Literature DB >> 29929199

Improvable Lifestyle Factors in Lymphoma Survivors.

Carla Minoia1, Sabino Ciavarella1, Giovanna Lerario1, Antonella Daniele2, Simona De Summa3, Mariarosaria Napolitano4, Attilio Guarini1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29929199     DOI： 10.1159/000489252

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  4 in total

Review 1.  Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training.

Authors:  Antonello Sica; Paola Vitiello; Andrea Ronchi; Beniamino Casale; Armando Calogero; Evangelista Sagnelli; Gilca Costa Nachtigal; Teresa Troiani; Renato Franco; Giuseppe Argenziano; Elvira Moscarella; Caterina Sagnelli
Journal:  Int J Environ Res Public Health       Date:  2020-01-29       Impact factor: 3.390

2.  An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.

Authors:  Antonello Sica; Caterina Sagnelli; Alfonso Papa; Massimo Ciccozzi; Evangelista Sagnelli; Armando Calogero; Erika Martinelli; Beniamino Casale
Journal:  Int J Environ Res Public Health       Date:  2020-03-16       Impact factor: 3.390

3.  Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin's Lymphoma Survivors.

Authors:  A Daniele; A Guarini; S De Summa; M Dellino; G Lerario; S Ciavarella; P Ditonno; A V Paradiso; R Divella; P Casamassima; E Savino; M D Carbonara; C Minoia
Journal:  J Pers Med       Date:  2021-03-17

Review 4.  Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.

Authors:  Sergio Di Molfetta; Antonella Daniele; Chiara Gerardi; Eleonora Allocati; Carla Minoia; Giacomo Loseto; Francesco Giorgino; Attilio Guarini; Vitaliana De Sanctis
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.